NCT07325253

A Pilot Study to Correlate 4-18F- Fluoro-1-naphthol 18F-4FN PET/CT Imaging With Chronic Graft Versus Host Disease Manifestations

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To study the safety and possible side effects of using the imaging agent 4-\[18F\]Fluoro-1-Naphthol (also called \[18F\]4FN) in PET/CT scans for participants with chronic GVHD.

Detailed description

Primary Objective: Determine the spatial and temporal correlation between \[18F\]4FN PET/CT measurements and the clinical manifestations and severity of chronic GVHD. Investigators hypothesize that \[18F\]4FN PET/CT imaging features will anatomically and by intensity (SUV) correlate with concurrent chronic GVHD manifestations. Investigators also hypothesize that PET/CT imaging features will temporally precede chronic GVHD manifestations at target anatomic locations.

Conditions

• Pilot Study
• PET/CT Imaging
• Host Disease Manifestation

Interventions

Type	Name	Description
DRUG	[18F]-4FN	Given by IV
OTHER	PET-CT	Imaging

Timeline

• Start date: 2025-11-18
• Primary completion: 2028-01-03
• Completion: 2030-01-03
• First posted: 2026-01-08
• Last updated: 2026-04-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study